GEn1E is a clinical-stage company utilizing a multi-target AI platform to develop first-in-class immunomodulators that specifically target kinase dysregulation in rare inflammatory diseases. Their approach employs novel allosteric binding mechanisms to enhance therapeutic specificity while minimizing off-target effects and toxicity associated with traditional kinase inhibitors.
Funding
$20M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Kinase dysregulation contributes to the pathogenesis of various inflammatory diseases. Previous attempts to address this dysregulation with kinase inhibitors have resulted in immunosuppression, off-target effects, toxicity, and a lack of specificity, potentially leading to severe medical complications. Targeting kinases with specificity while maintaining normal cellular functions remains a complex challenge.
Solution
GEn1E is developing first-in-class immunomodulators that target kinase dysregulation in rare inflammatory diseases using a multi-target AI platform. The company's approach involves identifying new binding pockets and utilizing novel allosteric binding mechanisms to enhance therapeutic specificity and minimize off-target effects. GEn1E's compounds act as selective and dual signal modifiers, offering a differentiated mechanism of action for treating inflammation compared to previous generation non-selective kinase inhibitors. The GRID™ AI platform accelerates drug discovery and clinical trials by connecting genes, pathways, proteins, diseases, and compounds through a rich database of curated data and machine learning models.
Target Audience
The primary target audience includes patients suffering from rare and inflammatory diseases, as well as pharmaceutical companies seeking novel therapies and strategic partnerships.
Features
- GRID™ AI platform for identifying novel drug targets and accelerating drug development.
- Novel allosteric binding mechanisms for enhanced therapeutic specificity.
- Selective and dual signal modifiers that avoid immunosuppression.
- First-in-class therapies targeting p38α:MK2 and ERK 1/2 kinases.
- Lead program GEn-1124 targeting ARDS.
- Preclinical programs for undisclosed targets and indications.